Answers are grounded in this paper and cite their sources.
Background Advanced cell therapies offer a promising strategy for restoring intervertebral disc (IVD) structure and function by targeting the biological mechanisms underlying disc degeneration. Despite encouraging preclinical results, significant barriers continue to limit successful clinical translation. Methods A systematic review was conducted in accordance with PRISMA guidelines. PubMed/MEDLINE, Embase, Scopus, and CINAHL were searched from database inception through June 2026 for studies evaluating advanced cell therapies for IVD regeneration. Eligible studies included preclinical and clinical investigations assessing stem cell–based therapies, biomaterial-assisted approaches, tissue-engineered constructs, gene-modified cellular products, extracellular vesicles, immunomodulatory strategies, and adjunctive biophysical stimulation. Data were extracted and synthesized qualitatively. Results Eighty-one studies met the inclusion criteria. Mesenchymal stromal cells (MSCs) were the most extensively investigated therapeutic platform, demonstrating regenerative, anti-inflammatory, and immunomodulatory effects in experimental models. Biomaterial scaffolds and hydrogel-based delivery systems enhanced cell retention, viability, and extracellular matrix production, while emerging approaches incorporating gene editing, extracellular vesicles, and biophysical stimulation showed potential to further improve therapeutic efficacy. However, the hostile microenvironment of the degenerated disc, characterized by hypoxia, nutrient deprivation, acidic pH, mechanical stress, and chronic inflammation, remained a major obstacle to long-term cell survival and functional integration. Clinical studies reported favorable safety profiles but demonstrated variable efficacy and were generally limited by small sample sizes and short follow-up periods. Conclusions Advanced cell therapies represent a promising approach for biological IVD regeneration, particularly when combined with biomaterials and emerging regenerative technologies. However, substantial challenges related to cell persistence, treatment standardization, regulatory approval, and the limited availability of high-quality clinical evidence continue to impede widespread clinical adoption. Future translational efforts should focus on optimizing therapeutic durability, improving patient selection, and generating robust long-term clinical data. Clinical trial number Not applicable.
No takes yet. Share an insight, caveat, or question.
Otukoya et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: